Skip to content

Study · Non-randomized trial · n = 9 · 1995

9 results

Methylene blue increases myocardial function in septic shock.

Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG

Critical care medicine1 Aug 1995Cited by 78 (Europe PMC)

PMID7634806 (opens in a new tab)DOI10.1097/00003246-199508000-00009 (opens in a new tab)PepBankPUB-07634806
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, methylene blue increased mean arterial pressure after 30 mins compared with baseline.

    In plain wordsMethylene blue increased mean blood pressure compared with baseline in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    IncreaseMean arterial pressure
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Measurements

    Mean arterial pressure
    84 mm Hg
    Before methylene blue (+/- 18)
    Mean arterial pressure
    109 mm Hg
    30 mins after starting infusion (+/- 31)

    Source sentences

    Summary
    Patients had a hyperdynamic circulation, and methylene blue increased (p < .01) mean arterial pressure from 84 +/- 18 to 109 +/- 31 mm Hg and cardiac index from 4.7 +/- 0.9 to 5.6 +/- 1.2 L/min/m2, before and 30 mins after starting the methylene blue infusion, respectively.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, methylene blue increased cardiac index after 30 mins compared with baseline.

    In plain wordsMethylene blue increased heart pumping output relative to body size compared with baseline in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    IncreaseCardiac index
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Measurements

    Cardiac index
    4.7 L/min/m2
    Before methylene blue (+/- 0.9)
    Cardiac index
    5.6 L/min/m2
    30 mins after starting infusion (+/- 1.2)

    Source sentences

    Summary
    Patients had a hyperdynamic circulation, and methylene blue increased (p < .01) mean arterial pressure from 84 +/- 18 to 109 +/- 31 mm Hg and cardiac index from 4.7 +/- 0.9 to 5.6 +/- 1.2 L/min/m2, before and 30 mins after starting the methylene blue infusion, respectively.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, cardiac filling pressures did not change after methylene blue.

    In plain wordsHeart filling pressures did not change from baseline after methylene blue in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    No significant changeCardiac filling pressures
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Source sentences

    Summary
    Cardiac filling pressures did not change.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, systemic vascular resistance index increased after methylene blue, but the result was not significant (p = .09).

    In plain wordsBlood vessel resistance increased without statistical significance compared with baseline after methylene blue in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    No significant changeSystemic vascular resistance index
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Source sentences

    Summary
    In the same time interval, the subnormal systemic vascular resistance index increased (p = .09) and arterial compliance decreased (p < .05).
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, methylene blue decreased arterial compliance compared with baseline.

    In plain wordsMethylene blue reduced artery flexibility compared with baseline in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    DecreaseArterial compliance
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Source sentences

    Summary
    In the same time interval, the subnormal systemic vascular resistance index increased (p = .09) and arterial compliance decreased (p < .05).
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, methylene blue increased oxygen delivery compared with baseline.

    In plain wordsMethylene blue increased oxygen delivery compared with baseline in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    IncreaseOxygen delivery
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Blood oxygenation and oxygen transport · Whole body
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Measurements

    Oxygen delivery
    714 mL/min/m2
    Baseline (+/- 188)
    Oxygen delivery
    865 mL/min/m2
    After methylene blue (+/- 250)

    Source sentences

    Summary
    Oxygen delivery and oxygen uptake increased (p < .05) from 714 +/- 188 to 865 +/- 250 mL/min/m2 and from 160 +/- 39 to 186 +/- 44 mL/min/m2, respectively.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, methylene blue increased oxygen uptake compared with baseline.

    In plain wordsMethylene blue increased oxygen uptake compared with baseline in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    IncreaseOxygen uptake
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Blood oxygenation and oxygen transport · Whole body
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Measurements

    Oxygen uptake
    160 mL/min/m2
    Baseline (+/- 39)
    Oxygen uptake
    186 mL/min/m2
    After methylene blue (+/- 44)

    Source sentences

    Summary
    Oxygen delivery and oxygen uptake increased (p < .05) from 714 +/- 188 to 865 +/- 250 mL/min/m2 and from 160 +/- 39 to 186 +/- 44 mL/min/m2, respectively.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, heart rate increased by 11 +/- 8 beats/min after methylene blue.

    In plain wordsHeart rate increased compared with baseline after methylene blue in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    IncreaseHeart rate
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Measurements

    Heart rate change
    11 beats/min
    Increase from baseline (+/- 8)

    Source sentences

    Summary
    Except for heart rate, which increased by 11 +/- 8 beats/min (p < .01), variables returned to baseline values at time = 120 mins.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with septic shock, measured variables except heart rate returned to baseline at 120 mins after methylene blue infusion started.

    In plain wordsMeasured variables except heart rate returned to baseline after methylene blue in patients with septic shock.

    Peptide
    Methylene blue
    Outcome
    Not applicableReturn of measured variables to baseline
    Study

    n = 9

    Comparator
    Baseline
    Outcome group
    Vascular function · Whole body
    Studied dose
    2 mg/kg · infusion · 20-min infusionAs given in this study (human).

    Source sentences

    Summary
    Except for heart rate, which increased by 11 +/- 8 beats/min (p < .01), variables returned to baseline values at time = 120 mins.
    3 context sentences
    Summary · context
    Open-label, nonrandomized clinical trial on the effects of methylene blue, an inhibitor of nitric oxide action.
    Summary · context
    Nine consecutive patients with documented septic shock and a pulmonary artery catheter in place, after initial resuscitation with fluids, sympathomimetics, and mechanical ventilation.
    Summary · context
    Hemodynamic and metabolic variables were measured before and then 15, 30, 60, and 120 mins after the start of a 20-min infusion of 2 mg/kg of methylene blue.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.